US · Healthcare · Biotechnology
EPS came in at -0.93 against a street estimate of -0.65 — a miss of 43.1%.
Analysts rate Bicara Therapeutics Inc. Common Stock a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $31.46.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 11.04% |
| T. Rowe Price Investment Management,Inc. | 10.05% |
| Siren, L.L.C. | 8.83% |
| Vestal Point Capital LP | 8.26% |
| Deep Track Capital, LP | 6.18% |
| HHG PLC | 5.08% |
| Red Tree Management, LLC | 4.81% |
| TPG GP A, LLC | 4.58% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 | 2026-07-28 |
| Shareholder vote results · Q2 2026 | 2026-06-10 |
| Company announcement · Q2 2026 | 2026-05-21 |
| Quarterly report · Q1 2026 | 2026-05-11 |
| Results announced · Q2 2026 | 2026-05-11 |
| Proxy statement · Q2 2026 | 2026-04-27 |
| Annual report FY2025 | 2026-03-30 |
| Quarterly report · Q3 2025 | 2025-11-10 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Bicara Therapeutics Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-08-05.